NEEDHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

Peer-reviewed publication in Journal for ImmunoTherapy of Cancer reports median overall survival of

NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

Novel systemic immune data demonstrated T-cell activation following local administration of aglatima

NEEDHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical

NEEDHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Candel Therapeutics, Inc. is upgraded from Buy to Strong Buy, driven by phase 3 success in localized

Analysts upgraded MAC, INVH, CIEN, AMH and CADL, raising ratings and several price targets.

B of A Securities analyst Alec Stranahan upgrades Candel Therapeutics (NASDAQ:CADL) from Neutral

Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure,

NEEDHAM, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

NEEDHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

NEEDHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds

B of A Securities analyst Alec Stranahan maintains Candel Therapeutics (NASDAQ:CADL) with a Neutr

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Candel Therapeutics (NASDAQ:CADL)

Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.52) per share which missed the an

NEEDHAM, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

Candel Therapeutics NASDAQ: CADL is advancing two off-the-shelf viral immunotherapy candidates desig

Candel Therapeutics, Inc. remains a Buy as its lead asset, CAN-2409, advances toward FDA submission

NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

NEEDHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

Stifel analyst Stephen Willey initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Buy

NEEDHAM, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

Candel Therapeutics is transitioning from a high-risk clinical-stage biotech to a late-stage oncolog

NEEDHAM, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical

Peer reviewed publication details pivotal data, demonstrating 30% improvement in disease-free surviv

Candel Therapeutics presented positive phase 3 prostate cancer data showing improved disease-free su

Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow

Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.14) per share which beat the anal

Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical

Candel Therapeutics ripped higher on Monday after a bullish analyst initiation, underscoring how nar

Citigroup analyst Yigal Nochomovitz maintains Candel Therapeutics (NASDAQ:CADL) with a Buy and ra

Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clini

Citigroup analyst Yigal Nochomovitz maintains Candel Therapeutics (NASDAQ:CADL) with a Buy and lo

Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.54) per share which missed the an

Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical

(Editor's note: The future prices of benchmark tracking ETFs, the lede, and the headline were up

Candel Therapeutics stock down on public offering pricing, intends to use proceeds for cancer therap